• Novacyt launched the Yourgene Insight DPYD test with EU IVDR certification, expanding access to regulated European clinical genetics markets.
• The assay detects 19 clinically relevant DPYD variants to help identify patients at higher risk of severe fluoropyrimidine chemotherapy toxicity.
• Novacyt described it as the first IVDR CE-marked DPYD test covering all Level 1 and Level 2 variants recommended by AMP and NCCN.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novacyt SA published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.